Compare PRCH & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRCH | DSGN |
|---|---|---|
| Founded | 2012 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 848.9M | 819.6M |
| IPO Year | 2019 | 2021 |
| Metric | PRCH | DSGN |
|---|---|---|
| Price | $11.06 | $14.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 4 |
| Target Price | ★ $18.63 | $15.25 |
| AVG Volume (30 Days) | ★ 2.2M | 493.9K |
| Earning Date | 04-28-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 90.91 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $482,414,000.00 | N/A |
| Revenue This Year | $4.15 | N/A |
| Revenue Next Year | $17.05 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.18 | N/A |
| 52 Week Low | $6.36 | $3.11 |
| 52 Week High | $19.44 | $17.25 |
| Indicator | PRCH | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 72.27 | 59.24 |
| Support Level | $8.93 | $9.71 |
| Resistance Level | $16.67 | $17.25 |
| Average True Range (ATR) | 0.72 | 1.16 |
| MACD | 0.29 | 0.01 |
| Stochastic Oscillator | 88.62 | 42.56 |
Porch Group Inc is a vertical software company reinventing the home services and insurance industries. It has four reportable segments: Insurance Services, Software & Data, Consumer Services, and Corporate. The majority of revenue is from the Insurance segment. The Insurance Services segment manages and operates the Reciprocal, providing services related, but not limited, to underwriting, policy renewal, risk management, insurance portfolio management, financial management, and setting investment guidelines in exchange for commissions and fees.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.